The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,332.00
Bid: 11,500.00
Ask: 12,400.00
Change: 0.00 (0.00%)
Spread: 900.00 (7.826%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: Miners Weigh On FTSE 100 Ahead Of US Nonfarm Payrolls

Fri, 06th Mar 2015 10:46

LONDON (Alliance News) - The FTSE 100 is trading lower mid-morning Friday, weighed upon by the mining sector, which has been dragged down by weak commodity prices as investors look ahead to the highly anticipated US nonfarm payrolls report.

The FTSE 100, which is heavily weighted in mining and resource stocks, is down 0.2% at 6,948.79, while the FTSE 250 is up 0.2% at 17,347.35, and the AIM All-Share is up 0.3% at 716.31.

In Europe, the French CAC 40 is down 0.2%, and the German DAX 30 is flat.

Fresnillo, down 2.5%, and Randgold Resources, down 1.9%, are the two biggest fallers in the FTSE 100 as gold prices continue to decline. The precious metal has fallen for the last four days and continues its negative trend, trading at USD1,194.53 an ounce.

Anglo American, down 1.5%, and Rio Tinto, down 0.7%, also are amongst the biggest fallers in the index after an Australian media report that iron ore prices fell to a fresh six-year low of USD59.30 a tonne. Rio also said Friday that it has increased its reserves in the Diavik diamond project, the Pilbara iron project and the Hail Creek Coal project.

Outside of mining, AstraZeneca, down 1.2%, also is one of the biggest fallers in the blue-chip index. The pharmaceutical giant guided that it expects its total revenue to decline by a mid-single digit percentage at constant exchange rates in 2015, in line with previous sales revenue guidance it gave at the time of its full-year results, as it announced changes to the way it presents its revenue. AstraZeneca maintained its core earnings per share guidance.

Shares in Weir Group lead FTSE 100 gainers, up 5.6% on press reports that the oil and gas service company could have attracted a bid from a US private equity firm. The Independent reports that GE Capital is linked with making a 2,800.00 pence per share bid, though it does attribute this to "starry-eyed punters". The stock is quoted at 1,830.36p.

Thomas Cook is the biggest gainer in the FTSE 250, up 19%. The travel operator said it has struck a strategic deal with Chinese investment group Fosun International Ltd under which the latter will acquire a 5% stake in the company. Thomas Cook said Fosun will pay GBP91.8 million to acquire 73.1 million shares Thomas Cook will issue to it, giving Fosun a 5% stake in the company. The shares are valued at 125.58 pence, compared to the travel firm's closing price Thursday of 120.60p. The stock currently trades at 143.90p.

Afren is the second-best performer in the index up 12%. The troubled oil and gas company, which will be relegated from the FTSE 250 on March 23, is looking to China to bring in "substantial" new capital, in the form of new equity, the Financial Times reported. Ethelbert Cooper, the Liberian entrepreneur who founded Afren, plans to recapitalize the company in partnership with a consortium of Chinese investors. This will become the first Africa-China partnership in the oil and gas sector listed in the UK.

Fourth quarter eurozone GDP met expectations to show quarter-on-quarter growth of 0.9%. The figure was a slight improvement on the third quarter reading of 0.8%. The year-on-year figure also matched estimates of a 0.3% growth, marginally higher than the 0.2% shown in the third quarter.

The euro had already fallen to a new 11-year low against the dollar ahead of the GDP results and continued lower afterward. The currency has reached a low Friday of USD1.0961.

The median expectations for UK inflation for the coming year was 1.9% in February compared to 2.5% in November, according to a survey from the Bank of England. This was its lowest level in more than 13 years. UK inflation had fallen to a record low 0.3% in January, dragged by falling motor fuel and food prices.

Still ahead in the economic calendar are the crucial US nonfarm payrolls, unemployment rate and average earnings figures, due at 1330 GMT.

By Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.